Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ: MCRB )

0.6384 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Via Benzinga
Recap: Seres Therapeutics Q2 Earnings
  Seres Therapeutics (NASDAQ:MCRB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug
Via Benzinga
Recap: Seres Therapeutics Q1 Earnings
Seres Therapeutics (NASDAQ:MCRB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy. 
Via Benzinga
Why Seres Therapeutics Shares Are Popping Off Today
Seres Therapeutics Inc (NASDAQ: MCRB) shares are trading higher by 13.24% to $6.12 Wednesday morning after the company announced it completed the rolling submission process for its BLA to the FDA for... 
Via Benzinga
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
  
Via Benzinga
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
  
Via Benzinga
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Earnings Preview: Seres Therapeutics
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Seres... 
Via Benzinga
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Why Is Pinterest Higher By 14%? 20 Stocks Moving In Friday's Pre-Market Session
Gainers United Maritime Corporation (NASDAQ: USEA) rose 55% to $3.41 in pre-market trading. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on... 
Via Benzinga
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and... 
Via Benzinga
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
From Seres Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million. 
Via Benzinga
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter. 
Via Benzinga
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.